First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI s...

por Müller, Volkmar, Ruhnke, Markus, Hoffmann, Oliver, Grafe, Andrea, Tomé, Oliver, Fett, Werner, Bruch, Harald-Robert, Sommer-Joos, Ann-Katrin, Schneeweiss, Andreas
Publicado 2021

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients

por Sehouli, Jalid, Mustea, Alexander, Oskay-Özcelik, Guelten, Keller, Maren, Richter, Rolf, Tomé, Oliver, Woopen, Hannah, Sommer-Joos, Ann-Katrin, Grabowski, Jacek P., Armbrust, Robert, Wimberger, Pauline
Publicado 2021

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern...

por Sehouli, Jalid, Tomè, Oliver, Dimitrova, Desislava, Camara, Oumar, Runnebaum, Ingo Bernhard, Tessen, Hans Werner, Rautenberg, Beate, Chekerov, Radoslav, Muallem, Mustafa Zelal, Lux, Michael Patrick, Trarbach, Tanja, Gitsch, Gerald
Publicado 2016

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era

por You, Benoit, Van Wagensveld, Lilian, Tod, Michel, Sonke, Gabe S., Horlings, Hugo M., Kruitwagen, R. F. P. M., Du Bois, Andreas, Selle, Frédéric, Perren, Timothy, Pfisterer, Jacobus, Joly, Florence, Cook, Adrian, Kaminsky, Marie Christine, Wollschlaeger, Kerstin, Lortholary, Alain, Tome, Oliver, Leary, Alexandra, Freyer, Gilles, Van Der Aa, Maaike, Colomban, Olivier
Publicado 2022